EVALUATION OF THE NOTIFICATION PROFILE OF ADVERSE EVENTS RELATED TO CHLOROQUINE AND AZITHROMYCIN BEFORE AND DURING THE COVID-19 PANDEMIC
Palavras-chave:
Chloroquine, Azithromycin, COVID-19, PharmacovigilanceResumo
This study evaluated the profile of adverse event notifications related to the use of Chloroquine and Azithromycin before and during the COVID-19 pandemic. The pandemic led to massive prescribing of these drugs, even without solid scientific evidence proving their efficacy against SARS-CoV-2. Using data from the VigiMed system, adverse event notifications were analyzed for the periods from January 2018 to December 2019 (pre-pandemic) and from March 2020 to December 2021 (pandemic). The results showed a significant increase in notifications during the pandemic, highlighting the severity of adverse effects associated with the indiscriminate use of these drugs. This study emphasizes the importance of evidence-based medical practices and rigorous pharmacovigilance to avoid unnecessary risks to public health. The conclusions reinforce the need for public policies focused on health education and the prevention of self-medication, especially in scenarios of health crises.
Referências
CHARY, M.A. et al. COVID-19: Therapeutics and Their Toxicities. Journal of Medical Toxicology, v. 16, p. 284-294, 2020.
CHEN, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, v. 395, n. 10223, p. 507-513, 2020.
DANZA, A. et al. Hidroxicloroquina no tratamento das doenças autoimunes sistêmicas. Revista Médica do Chile, v. 144, n. 2, p. 232-240. Chile, 2015.
FURTADO, H.M.R. et al. Azithromicin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet, v. 396, p.
-967, 2020
JOHNSTON, C. et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. EClinical Medicine, v. 33, 2021.
SAID, S.A.A. et al. Monoterapia versus politerapia de enoxaparina e hidroxicloroquina para o tratamento de COVID-19: um ensaio clínico controlado randomizado. Pharmacy Practice, v. 21, n. 1, p. 1-7, 2023.
SANTOS, A. C. et al. Investigação original: reações adversas a medicamentos usados para a COVID-19 em cinco países da América Latina. Revista Panamericana de Saúde Pública, Washington, v. 47, n. 1, p. 45-58, 2023. Disponível em: https://doi.org/10.26633/RPSP.2023.0047. Acesso em: 28 ago. 2024.
WALKER, P.G.T. et al. The impact of COVID-19 and strategies for mitigation and suppression in low-and middle-income countries. Science, v. 369, n. 6502, p. 413-422, 2020.
